NASDAQ:KIN - Kindred Biosciences Stock Price, Forecast & News

Kindred Biosciences trades on the NASDAQ under the ticker symbol "KIN."

Kindred Biosciences Inc (NASDAQ:KIN) released its quarterly earnings data on Tuesday, November, 12th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by $0.02. The biopharmaceutical company had revenue of $1.10 million for the quarter, compared to analyst estimates of $1.55 million. Kindred Biosciences had a negative return on equity of 58.86% and a negative net margin of 1,461.28%. View Kindred Biosciences' Earnings History.

Kindred Biosciences is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for Kindred Biosciences.

8 analysts have issued 1-year target prices for Kindred Biosciences' shares. Their forecasts range from $8.50 to $25.00. On average, they expect Kindred Biosciences' stock price to reach $14.44 in the next twelve months. This suggests a possible upside of 53.6% from the stock's current price. View Analyst Price Targets for Kindred Biosciences.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kindred Biosciences in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kindred Biosciences.

Headlines about KIN stock have been trending negative recently, according to InfoTrie Sentiment. The research group scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Kindred Biosciences earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Kindred Biosciences.

Kindred Biosciences saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 753,000 shares, an increase of 16.2% from the January 15th total of 648,200 shares. Based on an average daily trading volume, of 126,400 shares, the short-interest ratio is currently 6.0 days. Currently, 2.1% of the shares of the stock are sold short. View Kindred Biosciences' Current Options Chain.

Some companies that are related to Kindred Biosciences include Nabriva Therapeutics (NBRV), Amneal Pharmaceuticals (AMRX), Madrigal Pharmaceuticals (MDGL), Theravance Biopharma (TBPH), BELLUS Health (BLUSF), Dicerna Pharmaceuticals (DRNA), IGM Biosciences (IGMS), Endo International (ENDP), Zogenix (ZGNX), Intra-Cellular Therapies (ITCI), Y-mAbs Therapeutics (YMAB), Rocket Pharmaceuticals (RCKT), Supernus Pharmaceuticals (SUPN), Athenex (ATNX) and Revance Therapeutics (RVNC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Kindred Biosciences investors own include CorMedix (CRMD), bluebird bio (BLUE), Amicus Therapeutics (FOLD), Opko Health (OPK), Progenics Pharmaceuticals (PGNX), TherapeuticsMD (TXMD), Cara Therapeutics (CARA), Corbus Pharmaceuticals (CRBP), Gilead Sciences (GILD) and Inovio Pharmaceuticals (INO).

Kindred Biosciences' stock is owned by many different of retail and institutional investors. Top institutional investors include Ariel Investments LLC (4.56%), Renaissance Technologies LLC (3.02%), State Street Corp (1.79%), UBS Group AG (0.37%), Bank of New York Mellon Corp (0.29%) and Charles Schwab Investment Management Inc. (0.25%). Company insiders that own Kindred Biosciences stock include Park West Asset Management Llc, Raymond Townsend and Richard Chin. View Institutional Ownership Trends for Kindred Biosciences.

KIN stock was sold by a variety of institutional investors in the last quarter, including Ariel Investments LLC, Goldman Sachs Group Inc. and Renaissance Technologies LLC. View Insider Buying and Selling for Kindred Biosciences.

KIN stock was purchased by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, State Street Corp, Cambridge Investment Research Advisors Inc., Edgewood Management LLC, UBS Group AG, Prudential Financial Inc., Barclays PLC and Banque Cantonale Vaudoise. View Insider Buying and Selling for Kindred Biosciences.

Shares of KIN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of KIN stock can currently be purchased for approximately $9.40.

Kindred Biosciences has a market capitalization of $367.45 million and generates $1.97 million in revenue each year. The biopharmaceutical company earns $-49,690,000.00 in net income (profit) each year or ($1.60) on an earnings per share basis. Kindred Biosciences employs 146 workers across the globe.View Additional Information About Kindred Biosciences.

The official website for Kindred Biosciences is http://kindredbio.com/.

Kindred Biosciences' mailing address is 1555 BAYSHORE HIGHWAY SUITE 200, BURLINGAME CA, 94010. The biopharmaceutical company can be reached via phone at 650-701-7901 or via email at [email protected]